BioLine Rx(BLRX)

盘后4.17-0.05-1.18%19:57 EDT

4.22+0.12+2.93%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
- Bioline Rx Ltd盘中异动早盘股价大跌5.31%
  市场透视 · 06-03 22:17
  Bioline Rx Ltd盘中异动早盘股价大跌5.31%
- Bioline Rx Ltd盘中异动快速下挫5.71%
  市场透视 · 06-02 21:32
  Bioline Rx Ltd盘中异动快速下挫5.71%
- Bioline Rx Ltd2025财年第一财季实现净利润5.13百万美元，同比增加837.07%
  市场透视 · 05-30
  Bioline Rx Ltd2025财年第一财季实现净利润5.13百万美元，同比增加837.07%
- Bioline Rx Ltd盘中异动早盘急速跳水7.37%报3.52美元
  市场透视 · 05-23
  Bioline Rx Ltd盘中异动早盘急速跳水7.37%报3.52美元
- Bioline Rx Ltd盘中异动股价大跌5.22%
  市场透视 · 05-22
  Bioline Rx Ltd盘中异动股价大跌5.22%
- Bioline Rx Ltd盘中异动股价大涨5.52%
  市场透视 · 05-21
  Bioline Rx Ltd盘中异动股价大涨5.52%
- Bioline Rx Ltd盘中异动早盘股价大跌5.25%
  市场透视 · 05-19
  Bioline Rx Ltd盘中异动早盘股价大跌5.25%
- Bioline Rx Ltd盘中异动股价大涨5.11%报3.25美元
  市场透视 · 05-17
  Bioline Rx Ltd盘中异动股价大涨5.11%报3.25美元
- Bioline Rx Ltd盘中异动下午盘股价大涨6.12%报3.35美元
  市场透视 · 05-10
  Bioline Rx Ltd盘中异动下午盘股价大涨6.12%报3.35美元
- Bioline Rx Ltd盘中异动下午盘股价大跌5.80%报3.24美元
  市场透视 · 05-06
  Bioline Rx Ltd盘中异动下午盘股价大跌5.80%报3.24美元
- Bioline Rx Ltd盘中异动临近午盘急速上涨6.30%报3.42美元
  市场透视 · 04-30
  Bioline Rx Ltd盘中异动临近午盘急速上涨6.30%报3.42美元
- Bioline Rx Ltd盘中异动大幅拉升5.59%报3.17美元
  市场透视 · 04-25
  Bioline Rx Ltd盘中异动大幅拉升5.59%报3.17美元
- Bioline Rx Ltd盘中异动股价大涨5.16%报3.05美元
  市场透视 · 04-23
  Bioline Rx Ltd盘中异动股价大涨5.16%报3.05美元
- Bioline Rx Ltd盘中异动早盘股价大涨5.09%报2.89美元
  市场透视 · 04-14
  Bioline Rx Ltd盘中异动早盘股价大涨5.09%报2.89美元
- Bioline Rx Ltd盘中异动大幅跳水5.03%
  市场透视 · 03-11
  Bioline Rx Ltd盘中异动大幅跳水5.03%
- Bioline Rx Ltd盘中异动下午盘股价大涨6.55%报3.27美元
  市场透视 · 03-06
  Bioline Rx Ltd盘中异动下午盘股价大涨6.55%报3.27美元
- Bioline Rx Ltd盘中异动早盘大幅下挫6.01%
  市场透视 · 03-04
  Bioline Rx Ltd盘中异动早盘大幅下挫6.01%
- Bioline Rx Ltd盘中异动快速跳水5.67%报3.16美元
  市场透视 · 03-03
  Bioline Rx Ltd盘中异动快速跳水5.67%报3.16美元
- Bioline Rx Ltd盘中异动急速下挫5.99%报3.45美元
  市场透视 · 02-26
  Bioline Rx Ltd盘中异动急速下挫5.99%报3.45美元
- Bioline Rx Ltd盘中异动急速拉升5.29%报3.78美元
  市场透视 · 02-25
  Bioline Rx Ltd盘中异动急速拉升5.29%报3.78美元
公司概况
公司名称
BioLine Rx
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.biolinerx.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
BioLineRx Ltd.2003年4月注册成立，并开始营业，是一家临床阶段的生物制药开发公司。该公司致力于查明，许可和开发比现有的可用的治疗方法，开发具有优势的或者可以解决为满足的医疗需要的候选药物。目前的开发管线包括六个临床阶段的候选治疗药物：BL-1040，一种用于预防急性心肌梗死后心室重塑的新型聚合物溶液，或AMI；BL-8040，一种用于治疗急性髓细胞白血病（AML）、干细胞动员和血液学适应症的新型多肽；BL-7010，一种用于治疗乳糜泻的新型聚合物；BL-5010，一种定制的、专有的、含有两种酸的新型制剂的笔状涂抹器，正在欧洲开发，作为一种用于非手术切除良性皮肤病变的医疗设备；BL-7040，一种用于治疗炎症性肠病的寡核苷酸，或IBD；以及BL-8020，一种可口服治疗丙型肝炎病毒（HCV）和病毒适应症的药物，其独特的作用机制涉及抑制宿主细胞中病毒诱导的自噬。
- 03-31
  年度报告
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2024-12-27
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2024-03-26
  [修订]年度报告
  Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
  Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
- 2024-03-26
  年度报告
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2023-12-29
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2023-10-27
  超过5%披露
  Form SC 13D - General statement of acquisition of beneficial ownership
  Form SC 13D - General statement of acquisition of beneficial ownership
- 2023-03-22
  年度报告
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2023-01-20
  员工持股计划
  S-8 - Securities to be offered to employees in employee benefit plans
  S-8 - Securities to be offered to employees in employee benefit plans
- 2022-09-09
  [修订]年度报告
  20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-03-16
  年度报告
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2022-02-11
  超过5%披露
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
- 2021-05-26
  财报披露
  6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
  6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
- 2021-02-23
  年度报告
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2021-02-23
  财报披露
  6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
  6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
- 2021-02-16
  超过5%披露
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
  SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals

分时
5日
日
周
月

数据加载中...

最高

4.47

今开

4.03

量比

0.05

最低

3.88

昨收

4.10

换手率

9.50%

BioLine Rx(BLRX)

公司概况

热议股票